Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 191

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK -Positive Non–Small-Cell Lung Cancer

Open access
Gadgeel, Shirish M., Shaw, Alice T., Govindan, Ramaswamy, Gandhi, Leena, Socinski, Mark A., Camidge, D. Ross, De Petris, Luigi, Kim, Dong-Wan, Chiappori, Alberto, Moro-Sibilot, Denis L., Duruisseaux, Michael, Crino, Lucio, De Pas, Tommaso, Dansin, Eric, Tessmer, Antje, Yang, James Chih-Hsin, Han, Ji-Youn, Bordogna, Walter, Golding, Sophie, Zeaiter, Ali, Ou, Sai-Hong Ignatius · 2016 · Journal of Clinical Oncology

Abstract

Purpose: Alectinib has shown activity in the CNS in phase I and II studies. To further evaluate this activity, we pooled efficacy and safety data from two single-arm phase II studies (NP28761 and NP28673; ClinicalTrials.gov identifiers: NCT01871805 and NCT01801111, respectively) in patients with ALK-positive non–small-cell lung cancer (NSCLC). Patients and Methods: Both studies included patients with ALK-positive NSCLC who had previously received crizotinib; all patients received alectinib 600 mg twice per day. The primary end point in both studies was independent review committee (IRC)–assessed objective response rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1). Additional end points (all by IRC) included CNS ORR (CORR), CNS disease control rate (CDCR), and CNS duration of response (CDOR). Results: One hundred thirty-six patients had baseline CNS metastases (60% of the overall study populations); 50 patients (37%) had measurable CNS disease at baseline. Ninety-five patients (70%) had prior CNS radiotherapy; 55 patients completed the CNS radiotherapy more than 6 months before starting alectinib. Median follow-up time was 12.4 months (range, 0.9 to 19.7 months). For patients with baseline measurable CNS disease, IRC CORR was 64.0% (95% CI, 49.2% to 77.1%), CDCR was 90.0% (95% CI, 78.2% to 96.7%), and median CDOR was 10.8 months (95% CI, 7.6 to 14.1 months). For patients with measurable and/or nonmeasurable baseline CNS disease, IRC CORR was 42.6% (95% CI, 34.2% to 51.4%), CDCR was 85.3% (95% CI, 78.2% to 90.8%), and median CDOR was 11.1 months (95% CI, 10.3 months to not evaluable). CORR was 35.8% (95% CI, 26.2% to 46.3%) for patients with prior radiotherapy (n = 95) and 58.5% (95% CI, 42.1% to 73.7%) for patients without prior radiotherapy (n = 41). As previously reported, alectinib was well tolerated, regardless of baseline CNS disease. Conclusion: Alectinib showed good efficacy against CNS metastases, in addition to systemic activity, in crizotinib-refractory ALK-positive NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.68.4639

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 191

Metadata

Authors
Gadgeel, S. M., Shaw, A. T., Govindan, R., Gandhi, L., Socinski, M. A., Camidge, D. R., De Petris, L., Kim, D.-W., Chiappori, A., Moro-Sibilot, D. L., Duruisseaux, M., Crino, L., De Pas, T., Dansin, E., Tessmer, A., Yang, J. C.-H., Han, J.-Y., Bordogna, W., Golding, S., Zeaiter, A., & Ou, S.-H. I.
Venue
Journal of Clinical Oncology
Published
2016-12-01
Volume
34
Issue
34
Pages
4079-4085
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2528370542
Cited by
191
References
3
FWCI
25.16
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK -Positive Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2016.68.4639
The paper
Gadgeel, S. M., Shaw, A. T., Govindan, R., Gandhi, L., Socinski, M. A., Camidge, D. R., De Petris, L., Kim, D.-W., Chiappori, A., Moro-Sibilot, D. L., Duruisseaux, M., Crino, L., De Pas, T., Dansin, E., Tessmer, A., Yang, J. C.-H., Han, J.-Y., Bordogna, W., Golding, S., . . . Ou, S.-H. I. (2016). Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK -Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.68.4639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.